These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 6729219)

  • 41. Medical adrenalectomy in patients with advanced breast cancer resistant to anti-oestrogen treatment.
    Murray RM; Pitt P
    Breast Cancer Res Treat; 1981; 1(2):91-5. PubMed ID: 7348572
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Breast cancer. The hormone factor.
    Wissing VS
    Am J Nurs; 1984 Sep; 84(9):1117-9. PubMed ID: 6566508
    [No Abstract]   [Full Text] [Related]  

  • 43. Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer.
    Berns EM; Foekens JA; Vossen R; Look MP; Devilee P; Henzen-Logmans SC; van Staveren IL; van Putten WL; Inganäs M; Meijer-van Gelder ME; Cornelisse C; Claassen CJ; Portengen H; Bakker B; Klijn JG
    Cancer Res; 2000 Apr; 60(8):2155-62. PubMed ID: 10786679
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Use of tamoxifen in advanced male breast cancer.
    Patterson JS; Battersby LA; Bach BK
    Cancer Treat Rep; 1980; 64(6-7):801-4. PubMed ID: 7427964
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Controversies in the medical management of breast cancer.
    Smith IE
    Postgrad Med J; 1985 Feb; 61(712):117-22. PubMed ID: 3983039
    [No Abstract]   [Full Text] [Related]  

  • 46. Ludwig Breast Cancer trial LBCS III: chemo- and endocrine adjuvant treatment in postmenopausal patients.
    Gelber RD
    Recent Results Cancer Res; 1984; 96():102-9. PubMed ID: 6396763
    [No Abstract]   [Full Text] [Related]  

  • 47. Prognosis and treatment of patients with breast tumors of one centimeter or less and negative axillary lymph nodes.
    Fisher B; Dignam J; Tan-Chiu E; Anderson S; Fisher ER; Wittliff JL; Wolmark N
    J Natl Cancer Inst; 2001 Jan; 93(2):112-20. PubMed ID: 11208880
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Tamoxifen in advanced male breast cancer.
    Aisner J; Ross DD; Wiernik PH
    Arch Intern Med; 1979 Apr; 139(4):480-1. PubMed ID: 435005
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Adjuvant endocrine therapy of breast cancer].
    Jonat W; Maass H
    ZFA (Stuttgart); 1983 Apr; 59(10):571-4. PubMed ID: 6868762
    [No Abstract]   [Full Text] [Related]  

  • 50. Rationale for sequential tamoxifen and anticancer drugs in adjuvant setting for patients with node- and receptor-positive breast cancer.
    Kim R; Tanabe K; Emi M; Uchida Y; Osaki A; Toge T
    Int J Oncol; 2005 Apr; 26(4):1025-31. PubMed ID: 15753998
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, oestrogen-receptor positive breast cancer patients. An update at 7 years of the 1st GROCTA (Breast Cancer Adjuvant Chemo-Hormone Therapy Cooperative Group) trial.
    Boccardo F; Rubagotti A; Amoroso D; Sismondi P; Genta F; Nenci I; Piffanelli A; Farris A; Castagnetta L; Traina A
    Eur J Cancer; 1992; 28(2-3):673-80. PubMed ID: 1591091
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Rational combinations of hormonal and cytostatic agents in disseminated forms of breast cancer].
    Garin AM; Dmitrieva NV; Vyshinskaia GV; Lichintser MR
    Vopr Onkol; 1987; 33(11):13-7. PubMed ID: 3686916
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Increasing the response rate to cytotoxic chemotherapy by endocrine means.
    Lippman ME; Cassidy J; Wesley M; Young RC
    J Steroid Biochem; 1985 Dec; 23(6B):1173-80. PubMed ID: 3005774
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Hormones and tumor therapy: current clinical status and future developments in endocrine therapy of breast cancer].
    Szepesi T; Schratter-Sehn AU
    Wien Klin Wochenschr; 1982 Sep; 94(17):463-9. PubMed ID: 6760557
    [TBL] [Abstract][Full Text] [Related]  

  • 55. First-generation genomic tests for breast cancer treatment.
    Andre F; Delaloge S
    Lancet Oncol; 2010 Jan; 11(1):6-7. PubMed ID: 20005177
    [No Abstract]   [Full Text] [Related]  

  • 56. Chemotherapy and hormonal therapy in stage III disease; inflammatory breast cancer.
    Ragaz J
    Curr Opin Oncol; 1990 Dec; 2(6):1068-87. PubMed ID: 2099838
    [No Abstract]   [Full Text] [Related]  

  • 57. [Steroid hormone receptors and cellular proliferative activity following the short-term use of tamoxifen and chlorotrianisene in breast cancer].
    Vyshinskaia GV; Murav'eva NI; Shelsputina ZF; Kuz'mina ZV; Nikolaeva TG
    Eksp Onkol; 1985; 7(5):66-8. PubMed ID: 4065023
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Rationale for combining tamoxifen and interferon in the treatment of advanced breast cancer.
    Porzsolt F; Otto AM; Trauschel B; Buck C; Wawer AW; Schönenberger H
    J Cancer Res Clin Oncol; 1989; 115(5):465-9. PubMed ID: 2478560
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The NIH Consensus Development Conference on Adjuvant Chemotherapy for Breast Cancer--a commentary.
    Lippman ME
    Breast Cancer Res Treat; 1985; 6(3):195-200. PubMed ID: 3841498
    [No Abstract]   [Full Text] [Related]  

  • 60. Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer.
    Fisher B; Dignam J; Wolmark N; DeCillis A; Emir B; Wickerham DL; Bryant J; Dimitrov NV; Abramson N; Atkins JN; Shibata H; Deschenes L; Margolese RG
    J Natl Cancer Inst; 1997 Nov; 89(22):1673-82. PubMed ID: 9390536
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.